Botanical species · safety record

Cyperus scariosus

The EFSA Compendium of Botanicals holds 4 constituent measurements and 1 adverse-effect record for Cyperus scariosus. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Cyperus scariosus R.Br.

4Constituent measurements

1Safety records

4Cited sources

2Licensed products (Canada)

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 2 licensed products naming Cyperus scariosus as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Source material stated

Rhizome

What the records describe

Constituents measured

Plant parts

Preparations

Effect types

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Alkaloids	Roots and other underground parts	Powder	—	Electron microscopical tests	Resolve DOI
Saponins	Roots and other underground parts	Powder	—	Electron microscopical tests	Resolve DOI
Beta-selinene	Roots and other underground parts	Essential oil	2.75 Percent	GC-MS	No resolvable identifier
Steroidal saponins	Leaves	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	No resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

Effect	Target tissue	Plant part	Preparation	Test organism	Test type	Source
Immunotoxicity	—	Roots and other underground parts	Solvent extraction	House mouse (as animal)	Short-term toxicity	No resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Adams, S. John., Kuruvilla, Gina R., Krishnamurthy, K. V., Nagarajan, M., Venkatasubramanian, Padma. Pharmacognostic and phytochemical studies on Ayurvedic drugs Ativisha and Musta . Revista brasileira de farmacognosia-brazilian journal of pharmacognosy, 2013, vol. 23, no. 3, p. 398-409. DOI
Chowdhury, Jasim Uddin., Yusuf, Mohammed., Hossain, Muhammad Muzaffar. Aromatic plants of Bangladesh: Chemical constituents of rhizome oil of Cyperus scariosus R. Br. Indian perfumer, 2005, p. 103-105.
Bhatt, S. K., Saxena, V. K., Singh, K. V. Stigmasta-5,24(28)-diene-3beta-O-alpha-L-rhamnopyranosyl-O-beta-D-arabinopyranoside from leaves of Cyperus scariosus R.Br. Indian journal of physical and natural sciences, 1982, p. 15-17.
Bhagwat, Deepak., Kharya, M. D., Bani, Sarang., Pandey, Anjali., Chauhan, Prashant Singh., Kour, Kiranjeet., Suri, K. A., Satti, N. K., Dutt, Prabhu. Cyperus scariosus Chloroform Fraction Inhibits T cell Responses in Balb/C Mice. TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2009, vol. 8, no. 5, p. 399-408.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature